The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Cardiovascular Disease After Hodgkin Lymphoma Treatment: 40-Year Disease Risk
Open accessAbstract
IMPORTANCE: Hodgkin lymphoma (HL) survivors are at increased risk of cardiovascular diseases. It is unclear, however, how long the increased risk persists and what the risk factors are for various cardiovascular diseases. OBJECTIVES: To examine relative and absolute excess risk up to 40 years since HL treatment compared with cardiovascular disease incidence in the general population and to study treatment-related risk factors for different cardiovascular diseases. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included 2524 Dutch patients diagnosed as having HL at younger than 51 years (median age, 27.3 years) who had been treated from January 1, 1965, through December 31, 1995, and had survived for 5 years since their diagnosis. EXPOSURES: Treatment for HL, including prescribed mediastinal radiotherapy dose and anthracycline dose. MAIN OUTCOMES AND MEASURES: Data were collected from medical records and general practitioners. Cardiovascular events, including coronary heart disease (CHD), valvular heart disease (VHD), and cardiomyopathy and congestive heart failure (HF), were graded according to the Common Terminology Criteria for Adverse Events, version 4.0. RESULTS: After a median follow-up of 20 years, we identified 1713 cardiovascular events in 797 patients. After 35 years or more, patients still had a 4- to 6-fold increased standardized incidence ratio of CHD or HF compared with the general population, corresponding to 857 excess events per 10,000 person-years. Highest relative risks were seen in patients treated before 25 years of age, but substantial absolute excess risks were also observed for patients treated at older ages. Within the cohort, the 40-year cumulative incidence of cardiovascular diseases was 50% (95% CI, 47%-52%). Fifty-one percent of patients with a cardiovascular disease developed multiple events. For patients treated before 25 years of age, cumulative incidences at 60 years or older were 20%, 31%, and 11% for CHD, VHD, and HF as first events, respectively. Mediastinal radiotherapy increased the risks of CHD (hazard ratio [HR], 2.7; 95% CI, 2.0-3.7), VHD (HR, 6.6; 95% CI, 4.0-10.8), and HF (HR, 2.7; 95% CI, 1.6-4.8), and anthracycline-containing chemotherapy increased the risks of VHD (HR, 1.5; 95% CI, 1.1-2.1) and HF (HR, 3.0; 95% CI, 1.9-4.7) as first events compared with patients not treated with mediastinal radiotherapy or anthracyclines, respectively. Joint effects of mediastinal radiotherapy, anthracyclines, and smoking appeared to be additive. CONCLUSIONS AND RELEVANCE: Throughout their lives, HL survivors treated at adolescence or adulthood are at high risk for various cardiovascular diseases. Physicians and patients should be aware of this persistently increased risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
The design and analysis of cohort studies
Breslow, N. E., & Day, N. E. (1987) · International Agency for Research on Cancer eBooks · Cited by 1,312
Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., Donaldson, S. S., Green, D. M., Sklar, C. A., Robison, L. L., et al. (2009) · BMJ · doi:10.1136/bmj.b4606 · Cited by 1,166
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Late cardiotoxicity after treatment for Hodgkin lymphoma
Aleman, B. M. P., van den Belt-Dusebout, A. W., De Bruin, M. L., van 't Veer, M. B., Baaijens, M. H. A., Boer, J. P. D., Hart, A. A. M., Klokman, W. J., Kuenen, M. A., Ouwens, G. M., et al. (2007) · Blood · doi:10.1182/blood-2006-07-034405 · Cited by 746
Self-citationLong-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease
Aleman, B. M. P., van den Belt-Dusebout, A. W., Klokman, W. J., van’t Veer, M. B., Bartelink, H., & van Leeuwen, F. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.131 · Cited by 716
Self-citationLandier, W., Bhatia, S., Eshelman, D. A., Forte, K. J., Sweeney, T., Hester, A. L., Darling, J., Armstrong, F. D., Blatt, J., Constine, L. S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.032 · Cited by 706
Hull, M. C. (2003) · JAMA · doi:10.1001/jama.290.21.2831 · Cited by 644
Specht, L., Yahalom, J., Illidge, T., Berthelsen, A. K., Constine, L. S., Eich, H. T., Girinsky, T., Hoppe, R. T., Mauch, P., Mikhaeel, N. G., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.05.005 · Cited by 582
Bowles, E. J. A., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., Allen, L. A., Nekhlyudov, L., Goddard, K. A. B., Davis, R. L., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs317 · Cited by 566
McGale, P., Darby, S. C., Hall, P., Adolfsson, J., Bengtsson, N.-O., Bennet, A. M., Fornander, T., Gigante, B., Jensen, M.-B., Peto, R., et al. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.06.016 · Cited by 459
Swerdlow, A. J., Higgins, C. D., Smith, P., Cunningham, D., Hancock, B. W., Horwich, A., Hoskin, P. J., Lister, A., Radford, J. A., Rohatiner, A. Z. S., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk029 · Cited by 452
Role of Cancer Treatment in Long-Term Overall and Cardiovascular Mortality After Childhood Cancer
Tukenova, M., Guibout, C., Oberlin, O., Doyon, F., Mousannif, A., Haddy, N., Guérin, S., Pacquement, H., Aouba, A., Hawkins, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2267 · Cited by 451
Cardiac disease following treatment of Hodgkin's disease in children and adolescents.
Hancock, S. L., Donaldson, S. S., & Hoppe, R. T. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1208 · Cited by 443
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen, F. E., Klokman, W. J., Hagenbeek, A., Noyon, R., van den Belt-Dusebout, A. W., van Kerkhoff, E. H., van Heerde, P., & Somers, R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.312 · Cited by 443
Self-citationvan Leeuwen, F. E., Klokman, W. J., Veer, M. B. V., Hagenbeek, A., Krol, A. D. G., Vetter, U. A. O., Schaapveld, M., van Heerde, P., Burgers, J. M. V., Somers, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.487 · Cited by 436
Self-citationNg, A. K., Bernardo, M. P., Weller, E., Backstrand, K. H., Silver, B., Marcus, K. C., Tarbell, N. J., Friedberg, J., Canellos, G. P., & Mauch, P. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.021 · Cited by 422
Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study
Kremer, L. C. M., van Dalen, E. C., Offringa, M., Ottenkamp, J., & Voûte, P. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.191 · Cited by 399
Raemaekers, J. M. M., André, M. P. E., Federico, M., Girinsky, T., Oumedaly, R., Brusamolino, E., Brice, P., Fermé, C., van der Maazen, R., Gotti, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.9298 · Cited by 387
Self-citationLong-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer
van den Belt-Dusebout, A. W., Nuver, J., de Wit, R., Gietema, J. A., ten Bokkel Huinink, W. W., Rodrigus, P. T. R., Schimmel, E. C., Aleman, B. M. P., & van Leeuwen, F. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7193 · Cited by 345
Self-citationMöller, T. R., Garwicz, S., Barlow, L., Winther, J. F., Glattre, E., Olafsdottir, G., Olsen, J. H., Perfekt, R., Ritvanen, A., Sankila, R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3173 · Cited by 259
Galper, S. L., Yu, J. B., Mauch, P. M., Strasser, J. F., Silver, B., LaCasce, A., Marcus, K. J., Stevenson, M. A., Chen, M. H., & Ng, A. K. (2011) · Blood · doi:10.1182/blood-2010-06-291328 · Cited by 253
Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy
Travis, L. B., Ng, A. K., Allan, J. M., Pui, C.-H., Kennedy, A. R., Xu, X. G., Purdy, J. A., Applegate, K., Yahalom, J., Constine, L. S., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr533 · Cited by 229
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma
Moser, E. C. (2006) · Blood · doi:10.1182/blood-2005-08-3392 · Cited by 174
Myrehaug, S., Pintilie, M., Tsang, R., Mackenzie, R., Crump, M., Chen, Z., Sun, A., & Hodgson, D. C. (2008) · Leukemia & Lymphoma · doi:10.1080/10428190802140873 · Cited by 168
Maraldo, M. V., Brodin, N. P., Aznar, M. C., Vogelius, I. R., af Rosenschöld, P. M., Petersen, R. H., & Specht, L. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt156 · Cited by 150
Review of the cardiac long‐term effects of therapy for Hodgkin lymphoma
Ng, A. K. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08713.x · Cited by 121
Maraldo, M. V., Brodin, N. P., Vogelius, I. R., Aznar, M. C., af Rosenschöld, P. M., Petersen, R. H., & Specht, L. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.09.020 · Cited by 99
Risk of multiple primary malignancies following treatment of Hodgkin lymphoma
van Eggermond, A. M., Schaapveld, M., Lugtenburg, P. J., Krol, A. D. G., de Boer, J. P., Zijlstra, J. M., Raemaekers, J. M. M., Kremer, L. C. M., Roesink, J. M., Louwman, M. W. J., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532184 · Cited by 76
Self-citationSieswerda, E., Postma, A., van Dalen, E. C., van der Pal, H. J. H., Tissing, W. J. E., Rammeloo, L. A. J., Kok, W. E. M., van Leeuwen, F. E., Caron, H. N., & Kremer, L. C. M. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr595 · Cited by 63
Self-citationAnthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-10-199705150-00020 · Cited by 59
Feijen, E. A. M., van der Pal, H. J. H., van Dalen, E. C., Mulder, R. L., Bárdi, E., Kuehni, C. E., Tissing, W. J. E., & Kremer, L. C. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100432 · Cited by 11
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citationZamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Metadata
- Authors
- van Nimwegen, F. A., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., Petersen, E. J., Raemaekers, J. M. M., Kok, W. E. M., Aleman, B. M. P., & van Leeuwen, F. E.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2015-06-01
- Volume
- 175
- Issue
- 6
- Pages
- 1007
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2131388913
- Cited by
- 514
- References
- 32
- FWCI
- 26.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.